autologous total tumor mrna and pp65 full length (fl) lysosomal associated membrane protein (lamp) mrna loaded dotap liposome vaccine administered intravenously (rna loaded lipid particles, rna-lps)
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2021 (NCT04573140)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04573140 | Phase 1 | Oct 26, 2021 | CureSearch, The Pacific Pediatric Neuro-Oncology Consortium, University of California, San Francisco, University of Florida |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CureSearch | Academic/Hospital | 1 | 0 | 1 | 2021 |
| The Pacific Pediatric Neuro-Oncology Consortium | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1